Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Nano-X Imaging Temettü

Temettü kriter kontrolleri 0/6

Nano-X Imaging şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.6%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$0.98
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Nano-X Imaging Q4 2021 Earnings Preview: Insight Coming Regarding This Binary Play

Mar 30

Monday's Drop Isn't Likely The Last One For Nano-X

Dec 28

Nano-X Imaging Stock Is A No-No Buy

Oct 11

We're Interested To See How Nano-X Imaging (NASDAQ:NNOX) Uses Its Cash Hoard To Grow

Aug 20

Nanox submits 510(k) application for first version of Nanox.ARC 3-D in U.S.

Jun 17

We're Not Worried About Nano-X Imaging's (NASDAQ:NNOX) Cash Burn

May 05

Here's What Nano-X Imaging Ltd.'s (NASDAQ:NNOX) Shareholder Ownership Structure Looks Like

Mar 08

Nano-X Imaging lower 10% on additional information request by FDA on Nanox.ARC version

Feb 01

Nano-X Imaging (NASDAQ:NNOX) Is In A Strong Position To Grow Its Business

Jan 13

Nano-X Imaging and USARAD extend strategic collaboration

Jan 05

Nano-X Vision Under The X-Ray

Dec 09

What Type Of Shareholders Make Up Nano-X Imaging Ltd.'s (NASDAQ:NNOX) Share Registry?

Nov 21

Nano-X Imaging EPS misses by $0.12

Nov 09

NANO-X Imaging: Novel Technology Or Outdated Technology?

Nov 02

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: NNOX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: NNOX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Nano-X Imaging Piyasaya Karşı Temettü Getirisi

NNOX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (NNOX)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Healthcare)	1.6%
Analist tahmini (NNOX) (3 yıla kadar)	n/a

Önemli Temettü: NNOX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, NNOX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: NNOX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: NNOX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Nano-X Imaging Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Nano-X Imaging: Bold Vision, Bearish Momentum, And High Investor Risk

Nano-X Imaging Ltd. to Report Q2, 2024 Results on Aug 20, 2024

Nano-X Imaging Ltd. Announces Resignation of So Young Shin as Member of the Board of Directors

Nano-X Imaging Ltd. to Report Q1, 2024 Results on May 28, 2024

Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?

Price target decreased by 26% to US$16.00

Full year 2023 earnings released: US$1.08 loss per share (vs US$2.17 loss in FY 2022)

Nano-X Imaging: System Deployments Finally Begin

Nano-X Imaging Ltd. to Report Q4, 2023 Results on Apr 01, 2024

Nanox Receives FDA Clearance for Healthfld

New minor risk - Share price stability

Price target decreased by 16% to US$18.30

Nano-X Imaging Ltd. Announces Demise of Ran Poliakine, Founder and Non-Executive Chairman

Nano-X Imaging Ltd. Elects Nehama Ronen as A Class I Director

No longer forecast to breakeven

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Nano-X Imaging Ltd., Annual General Meeting, Dec 27, 2023

Nano-X Imaging Ltd. to Report Q3, 2023 Results on Nov 28, 2023

New minor risk - Share price stability

Consensus EPS estimates fall by 15%

Price target decreased by 12% to US$28.25

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Nano-X Imaging Ltd. to Report Q2, 2023 Results on Aug 17, 2023

Consensus revenue estimates decrease by 24%, EPS upgraded

Nano-X Imaging Ltd. Reports Unaudited Consolidated Impairment of Property and Equipment for the First Quarter Ended March 31, 2023

Nano-X Imaging Ltd. to Report Q1, 2023 Results on May 22, 2023

Consensus revenue estimates decrease by 19%, EPS upgraded

Price target decreased to US$28.25

Forecast to breakeven in 2025

Nano-X Imaging Ltd., Annual General Meeting, Dec 28, 2022

Less than half of directors are independent

Nano-X Imaging Ltd., Annual General Meeting, Dec 21, 2022

Nano-X Imaging Ltd. to Report Q3, 2022 Results on Nov 10, 2022

Nano-X Imaging Ltd Submits 510(K) Premarket Notification to the U.S. Food and Drug Administration

Nano-X Imaging gains on FDA submission for new digital X-ray technology

Consensus revenue estimates fall by 14%

Nano-X Imaging Ltd. Reports Goodwill Impairment for the Quarter Ended on June 30, 2022

Nano-X Imaging Q2 Earnings Preview

Nano-X Imaging Ltd. to Report Q2, 2022 Results on Aug 16, 2022

Nano-X: Too Controversial To Buy

Founder & Chairman notifies of intention to sell stock

Nano-X Imaging Ltd. Announces Demise of Richard Stone, Director

No longer forecast to breakeven

Consensus EPS estimates fall by 31%

Nano-X Imaging Ltd. to Report Q1, 2022 Results on May 19, 2022

Price target decreased to US$46.00

Less than half of directors are independent

Consensus revenue estimates increase by 79%

Nano-X Imaging Q4 2021 Earnings Preview: Insight Coming Regarding This Binary Play

Nano-X Imaging Ltd. to Report Q4, 2021 Results on Mar 31, 2022

Nano-X Imaging Ltd. Announces It Has Submitted with the Food and Drug Administration Q-Submission for Second Version of Multi-Source Nanox

Nano-X Imaging Ltd. Announces Issuance of American Medical Association New Category III CPT Code for Its Coronary Artery Calcium Population Health Solution

Forecast to breakeven in 2024

Monday's Drop Isn't Likely The Last One For Nano-X

Price target increased to US$50.50

Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Against Nano-X Imaging Ltd

Director notifies of intention to sell stock

Nano-X Imaging Stock Is A No-No Buy

We're Interested To See How Nano-X Imaging (NASDAQ:NNOX) Uses Its Cash Hoard To Grow

Nano-X Imaging Ltd. (NasdaqGM:NNOX) entered into a binding letter of intent to acquire USARAD Holdings Inc. and All of the Assets of MDW, LLC for $30 million.

Nano-X Imaging Ltd. (NasdaqGM:NNOX) entered into an agreement to acquire Zebra Medical Vision Ltd for $200 million.

Nano-X Imaging Ltd. Announces U.S. Food and Drug Administration 510(K) Submission for First Version of Multi-Source Nanox.ARC

Nanox submits 510(k) application for first version of Nanox.ARC 3-D in U.S.

Forecast breakeven pushed back to 2024

We're Not Worried About Nano-X Imaging's (NASDAQ:NNOX) Cash Burn

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Here's What Nano-X Imaging Ltd.'s (NASDAQ:NNOX) Shareholder Ownership Structure Looks Like

Nano-X Imaging Ltd. Demonstrates Nanox.ARC At 2020 Radiology Society of North America; Submits Comprehensive Response to the U.S. Food and Drug Administration

New 90-day low: US$41.67

Nano-X Imaging Ltd. to Report Q4, 2020 Results on Mar 02, 2021

Nano-X Imaging Ltd. Appoints Mr. Dan Suesskind and Mrs. Noga Kainan as External Directors

Nano-X Imaging Ltd. Receives Additional Information Requests from the FDA Which, Among Other Things, Require to Address Certain Deficiencies and Questions

Nano-X Imaging lower 10% on additional information request by FDA on Nanox.ARC version